Published in Hepatitis Weekly, June 13th, 2005
Researchers in Taiwan conducted a study "to prospectively evaluate the feasibility of using power Doppler ultrasonography (US) and measurement of circulating angiogenic factors to assess the antiangiogenic effect of thalidomide in hepatocellular carcinoma. The Ethics Committee of the National Taiwan University Hospital approved the study, and all patients gave prior written informed consent."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.